乙型肝炎表面抗原泛素化修饰的研究进展  

Progress in research of ubiquitination modification of hepatitis B surface antigen

作　　者：牛安行 刘锦 朱传武[1] An-Xing Niu;Jin Liu;Chuan-Wu Zhu(Department of Hepatology and Infectious Diseases,The Fifth People’s Hospital of Suzhou,The Affiliated Infectious Diseases Hospital of Soochow University,Suzhou 215131,Jiangsu Province,China)

机构地区：[1]苏州市第五人民医院,苏州大学附属传染病医院感染、肝病科,江苏省苏州市215131

出　　处：《世界华人消化杂志》2024年第5期333-338,共6页World Chinese Journal of Digestology

基　　金：国家自然科学基金项目,No.82172252和No.82002194;江苏省自然科学基金项目,No.BK20211080;苏州姑苏卫生人才计划项目,No.GSWS2020091.

摘　　要：慢性乙型肝炎(chronic hepatitis B,CHB)患者体内存在的大量亚病毒颗粒可以诱导免疫耐受,导致乙型肝炎病毒(hepatitis B virus,HBV)的持续感染.患者要实现功能性治愈的目标,则需要获得血清乙型肝炎表面抗原(hepatitis B surface antigen,HBsAg)的消失,但目前临床上尚缺乏有效抑制HBV共价闭合环状DNA的有效药物,因此HBsAg很难被清除.蛋白质的泛素化修饰是HBsAg降解的一条潜在路径,这将有可能改变HBV的生存和免疫环境.本文重点对有关HBsAg的泛素化,包括类泛素化和去泛素化的研究进行综述,以期为CHB抗病毒治疗探索新的途径提供参考.The large number of subviral particles existing in chronic hepatitis B(CHB)patients can induce immune tolerance,leading to persistent infection with hepatitis B virus(HBV).In order to achieve the goal of functional cure,patients need to obtain the disappearance of serum hepatitis B surface antigen(HBsAg).However,currently there is still a lack of effective drugs to inhibit HBV covalently closed circular DNA,and thus HBsAg is difficult to be removed.Ubiquitination modification of proteins is a potential path for HBsAg degra-dation,which would have the potential to alter the HBV survival and immune environment.This review focuses on the ubiquitination of HBsAg,including neddylation and deubiquitination,in order to explore new approaches of antiviral therapy in CHB.

关 键 词：乙型肝炎表面抗原 泛素化 类泛素化 去泛素化 

分 类 号：R512.62[医药卫生—内科学]